Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Solid Tumors
This is a phase I, single-arm, open-label, single-center study to establish the recommended infusion schedule for Troxatyl™ administered as a continuous infusion for 2-5 days to subjects with solid tumors.
Neoplasms
DRUG: Troxatyl™ (Cytotoxic Chemotherapeutic)
To determine the recommended infusion schedule for the investigational new drug administered as a continuous infusion, and to define the safety tolerance and dose limiting toxicities.
Pharmacokinetic/pharmacodynamic profile, preliminary evidence of the anti-tumor activity.
This is a phase I, single-arm, open-label, single-center study to establish the recommended infusion schedule for Troxatyl™ administered as a continuous infusion for 2-5 days to subjects with solid tumors.